The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321 + pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.
 
Marios Giannakis
Research Funding - Janssen; Servier
Patents, Royalties, Other Intellectual Property - Patent pending on biomarkers of immune response
 
Dung T. Le
Honoraria - Merck
Consulting or Advisory Role - Bristol-Myers Squibb; HalioDX; Janssen; Merck; Merus NV; Nouscom
Research Funding - Abbvie (Inst); Aduro Biotech; Bristol-Myers Squibb; Curegenix; Medivir; Merck; Nouscom (Inst)
Patents, Royalties, Other Intellectual Property - Inventor of technology, "Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition".
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera; Targeting Resistance in Cancer Cooperative; Tumor Board Tuesday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; IDEAYA Biosciences; Merck; Merus; Novartis; Pfizer; Pionyr; Seagen; TriSalus Life Sciences
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); RenovoRx (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm; Use patent for veliparib and FOLFOX
Travel, Accommodations, Expenses - Astellas Pharma
 
Benjamin Adam Weinberg
Employment - Apple (I)
Stock and Other Ownership Interests - Apple (I)
Honoraria - Rafael Pharmaceuticals
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bayer; DoMore Diagnostics; HalioDx; Merus NV
Speakers' Bureau - AstraZeneca; Bayer; Diiachi Sankyo; HalioDx; Lilly; Seagen; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Ipsen (Inst); Isofol Medical (Inst); Novartis (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Boehringer Ingelheim; Caris Life Sciences; Merus NV
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche; Sanofi
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); CANbridge Pharmaceuticals (Inst); Jacobio (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)
 
Jifang Gong
No Relationships to Disclose
 
Jian Li
No Relationships to Disclose
 
John H Strickler
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Inivata; Lilly; Natera (Inst); Pfizer; Pionyr; Roche/Genentech; Seagen; Silverback Therapeutics; Takeda; Viatris; Zentalis
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene; Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Leap Therapeutics (Inst); Lilly (Inst); Nektar (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Travel, Accommodations, Expenses - Seagen
 
Aiping Zhou
No Relationships to Disclose
 
Wen Zhang
No Relationships to Disclose
 
Aparna Raj Parikh
Consulting or Advisory Role - Abbvie; Bayer; Biofidelity; Checkmate Pharmaceuticals; CVS; Delcath Systems; Delcath Systems; Foundation Medicine; Genconn Biotech; Genconn Biotech; Guardant Health; Illumina; Inivata; Lilly; Natera; Pfizer; Roche/Genentech; SAGA Diagnostics; Scarce; Seagen; Taiho Oncology; UpToDate; Value Analytics Labs; xCures; xCures
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Erasca, Inc; Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Plexxikon (Inst); PMV Pharma; PureTech (Inst)
Other Relationship - C2i genomics; Parithera; Xact Robotics
 
Dustin A. Deming
Consulting or Advisory Role - Bayer; Lilly; Pfizer; Seagen
Research Funding - AADi (Inst); Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Natera (Inst); Promega (Inst); Revolution Medicines (Inst); Strata Oncology (Inst)
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Rocky Mountain Oncology Society
Consulting or Advisory Role - Abbvie (Inst); BostonGene (Inst); BostonGene (Inst); EMD Serono; Fujifilm (Inst); Inspirna (Inst); Jubilant Pharmaceuticals (Inst); Merck (Inst); Navire (Inst); Predicine (Inst); Regeneron (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Teon Therapeutics (Inst); Turning Point Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); Accutar Biotech (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunitas (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jazz Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Metabomed (Inst); Millennium (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Navire (Inst); NiKang Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); Poseida (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Silicon Therapeutics (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tallac Therapeutics (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst); Zhuhai Yufan Biotechnologies (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute; Synthorx/Sanofi
 
Jinjin Cai
Employment - Curegenix
 
Laurie Rosenstein
No Relationships to Disclose
 
Andrew Dorr
Employment - SciQ (I)
Leadership - Cend Therapeutics; Circle Pharma; Curegenix; Delta TpX; Fortis; Phoenix Molecular Designs; Pic Therapeutics; Tanabe Research; Virtuoso Therapeutics; Vivace Therapeutics
Consulting or Advisory Role - Cend Therapeutics; Circle Pharma; Curegenix; Delta TpX; Fortis; Phoenix Molecular Designs; PIC Therapeutics; PIC Therapeutics; Virtuoso Therapeutics; Vivace Therapeutics
Patents, Royalties, Other Intellectual Property - Fortis Therapeutics patients
 
Michael Michael An
Employment - Curegenix; Curegenix
Leadership - Curegenix; Curegenix
Stock and Other Ownership Interests - Curegenix; Curegenix